C Moore1, Y Wang, A G Ramage. 1. Department of Pharmacology, University College London, London, UK.
Abstract
BACKGROUND AND PURPOSE: Central application of nicotine causes the release of vasopressin and affects blood pressure. Involvement of the 5 neuronal nicotinic receptor groups, alpha2(*)-alpha7(*) in these effects is unknown. The availability of selective agonists for alpha7 (PSAB-OFP) and alpha4beta2 (TC-2559) nACh receptors allowed their role to be investigated. EXPERIMENTAL APPROACH: Recordings were made of arterial blood pressure, heart rate and renal sympathetic nerve activity in anaesthetized male rats with neuromuscular blockade and artificial respiration. Effects of the agonists, PSAB-OFP (1-10 micromol kg(-1)) and TC-2559 (1-10 micromol kg(-1)) on these variables given intracerebroventricularly (i.c.v.) and intracisternally (i.c.) in the presence or absence of the antagonists, DhbetaE (10 micromol kg(-1)) and MLA (0.5 micromol kg(-1)), for the appropriate nicotinic receptor subtypes, respectively, and a V(1) receptor antagonist, given i.v. or centrally, were investigated. KEY RESULTS: Both agonists given i.c.v. caused a delayed rise in blood pressure and renal nerve activity which could be blocked only with the appropriate antagonist. The agonists had an earlier onset of action when given i.c., favouring the brainstem as the major site of action. The effects of these agonists were also attenuated by the V(1) receptor antagonist given i.v. and blocked when this antagonist was given centrally. Antagonists had no effect on baseline variables. CONCLUSIONS AND IMPLICATIONS: Activation of alpha4beta2 and alpha7 receptors in the brainstem is mainly responsible for the cardiovascular effects of activating these receptors, which have a similar profile of action. These actions, although independent, are mediated by the central release of vasopressin.
BACKGROUND AND PURPOSE: Central application of nicotine causes the release of vasopressin and affects blood pressure. Involvement of the 5 neuronal nicotinic receptor groups, alpha2(*)-alpha7(*) in these effects is unknown. The availability of selective agonists for alpha7 (PSAB-OFP) and alpha4beta2 (TC-2559) nACh receptors allowed their role to be investigated. EXPERIMENTAL APPROACH: Recordings were made of arterial blood pressure, heart rate and renal sympathetic nerve activity in anaesthetized male rats with neuromuscular blockade and artificial respiration. Effects of the agonists, PSAB-OFP (1-10 micromol kg(-1)) and TC-2559 (1-10 micromol kg(-1)) on these variables given intracerebroventricularly (i.c.v.) and intracisternally (i.c.) in the presence or absence of the antagonists, DhbetaE (10 micromol kg(-1)) and MLA (0.5 micromol kg(-1)), for the appropriate nicotinic receptor subtypes, respectively, and a V(1) receptor antagonist, given i.v. or centrally, were investigated. KEY RESULTS: Both agonists given i.c.v. caused a delayed rise in blood pressure and renal nerve activity which could be blocked only with the appropriate antagonist. The agonists had an earlier onset of action when given i.c., favouring the brainstem as the major site of action. The effects of these agonists were also attenuated by the V(1) receptor antagonist given i.v. and blocked when this antagonist was given centrally. Antagonists had no effect on baseline variables. CONCLUSIONS AND IMPLICATIONS: Activation of alpha4beta2 and alpha7 receptors in the brainstem is mainly responsible for the cardiovascular effects of activating these receptors, which have a similar profile of action. These actions, although independent, are mediated by the central release of vasopressin.
Authors: Lisa M Broad; Catherine Felthouse; Ruud Zwart; Gordon I McPhie; Kathy H Pearson; Peter J Craig; Louise Wallace; Richard J Broadmore; John R Boot; Martine Keenan; S Richard Baker; Emanuele Sher Journal: Eur J Pharmacol Date: 2002-10-04 Impact factor: 4.432
Authors: Manuel Ferreira; Niaz Sahibzada; Min Shi; William Panico; Mark Niedringhaus; Adam Wasserman; Kenneth J Kellar; Joseph Verbalis; Richard A Gillis Journal: J Neurosci Date: 2002-04-01 Impact factor: 6.167
Authors: J Brek Eaton; Jian-Hong Peng; Katherine M Schroeder; Andrew A George; John D Fryer; Chandra Krishnan; Lori Buhlman; Yen-Ping Kuo; Ortrud Steinlein; Ronald J Lukas Journal: Mol Pharmacol Date: 2003-12 Impact factor: 4.436
Authors: Yantao Zuo; Hanbing Lu; D Bruce Vaupel; Yi Zhang; Svetlana I Chefer; William R Rea; Anna V Moore; Yihong Yang; Elliot A Stein Journal: Neuropsychopharmacology Date: 2011-07-27 Impact factor: 7.853
Authors: Lee H Sterling; Sarah B Windle; Kristian B Filion; Lahoud Touma; Mark J Eisenberg Journal: J Am Heart Assoc Date: 2016-02-22 Impact factor: 5.501